Self-driving laboratories: A paradigm shift in nanomedicine development.
Matter
; 6(4): 1071-1081, 2023 Apr 05.
Article
en En
| MEDLINE
| ID: mdl-37020832
Nanomedicines have transformed promising therapeutic agents into clinically approved medicines with optimal safety and efficacy profiles. This is exemplified by the mRNA vaccines against COVID-19, which were made possible by lipid nanoparticle technology. Despite the success of nanomedicines to date, their design remains far from trivial, in part due to the complexity associated with their preclinical development. Herein, we propose a nanomedicine materials acceleration platform (NanoMAP) to streamline the preclinical development of these formulations. NanoMAP combines high-throughput experimentation with state-of-the-art advances in artificial intelligence (including active learning and few-shot learning) as well as a web-based application for data sharing. The deployment of NanoMAP requires interdisciplinary collaboration between leading figures in drug delivery and artificial intelligence to enable this data-driven design approach. The proposed approach will not only expedite the development of next-generation nanomedicines but also encourage participation of the pharmaceutical science community in a large data curation initiative.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Matter
Año:
2023
Tipo del documento:
Article
País de afiliación:
Canadá
Pais de publicación:
Estados Unidos